Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations

AIDS

Volumn 17, Issue 3, 2003, Pages 442-444

  Gonzàlez De Requena, Daniel ^a   Núñez, Marina ^a   De Mendoza, Carmen ^a   Jiménez Nàcher, Inmaculada ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 0037436236     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200302140-00020     Document Type: Article

References (11)

1. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, et al. Mechanism of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy (Trilege). JAMA 2000;283:205-211.
2. Markowitz M. Resistance, fitness, and potency. Mapping the paths to virological failure. JAMA 2000, 283:250-251.
3. Austin D, Ferguson N, Fraser C, Roms K. Understanding antiviral treatment failure: the role of pharmacokinetic/dynamycs and patient non-compliance in the emergence of resistance. In: 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, October 1999 [Abstract 212].
4. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, et al. Incidence and predictors of virological failure of antiretroviral triple drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999, 15:1631-1638.
5. Hill A, Stirnadel H. Are clinical trials of TDM underpowered to detect effects on HIV-RNA? Three stage modelling of samples sizes. In: 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, April 2001 [Abstract 6.9].
6. Nuñez M, de Mendoza C, Valer L, Casas E, Lopez-Calvo S, Castro A, et al. Resistance mutations in patients experiencing early failure with nelfinavir-containing triple combinations. Med Sci Monitor 2002, 8:620-623.
7. Hugen P, Verweij-van Wissen C, Burger D, Wuis E, Koopmans P, Kekster Y. Simultaneous determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 1999, 727:139-149.
8. Burger D, Hugen P, Aarnoutse R, Baede P, Niewkerk P, Koopmans P, et al. Treatment failure of NFV containing triple therapy can largely be explained by low NFV plasma concentrations. AIDS 2000, 14 (Suppl. 4):88.
9. Durant J, Clevenberg P, Garraffo R, Halfon, P, Icard S, Del Giudice P, et al. Importance of protease inhibitors plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000, 14:1333-1339.
10. Casado J, Moreno S, Hertogs K, Dronda F, Antela A, Dehertogh P, et al. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 2002, 16:47-52.
11. Burger D, Hugen P, Droste J, Huitema A. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive patients improves therapeutic outcomes after 1 year: results from ATHENA. In: 1st IAS Conference. Buenos Aires, July 2001 [Abstract 30].